ArticleArchives of endocrinology and metabolism2025
Serum microRNA analysis facilitates decision-making between active surveillance and immediate surgery for low-risk thyroid tumors.
Article in Archives of endocrinology and metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo develop a practical and cost-effective test to distinguish patients with malignant thyroid nodules eligible for active surveillance from those requiring immediate surgery.
methodsThis prospective observational study included patients with malignant thyroid nodules (3 to 15 mm) who were assigned to either an Active Surveillance Group (n = 30) or a Surgery Group (n = 21) based on the institutional protocol. The Surgery Group was further stratified according to the American Thyroid Association risk of recurrence/persistence. Preoperative serum levels of miR-146b-5p and miR-204, normalized to miR-16, were analyzed. Receiver operating characteristic curves were used to establish cut-off values to differentiate between low and intermediate/high risk of recurrence/persistence, which were subsequently applied to the Active Surveillance Group.
resultsPatients were initially assigned to the active surveillance (n = 30; 53.5 ± 12.6 years old) or Surgery Group (n = 21; 41.9 ± 7.9 years old). The mean follow-up duration for the Active Surveillance Group was 36.4 ± 25.8 months, during which no patients experienced disease progression. Five patients in the Active Surveillance Group were subsequently transitioned to the Surgery Group. Molecular analysis of the Surgery Group indicated that upregulation of miR-146b-5p/miR-16 and downregulation of miR-204/miR-16 were significantly associated with intermediate/high risk of recurrence/persistence (p = 0.005 and 0.006, respectively). Downregulation of miR-204/miR-16 demonstrated a sensitivity of 75% and a negative predictive value of 86.7%. The combination of upregulation of miR-146b-5p/miR-16 and downregulation of miR-204/miR-16 yielded both a specificity and negative predictive value of 100%.
conclusionDecision-making for patients with low-risk papillary thyroid carcinoma regarding eligibility for active surveillance can be facilitated through serum analysis of miR-204/miR-16 expression, which may be used as a rule-out test. In contrast, combined analysis of miR-146b-5p/miR-16 and miR-204/miR-16 can serve as a rule-in test.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.